Pharma

Pharma

Novartis expands Rhapsido's growing reach in chronic hives

After a first approval in chronic hives, Novartis’ Rhapsido is expanding its reach with a new FDA nod that comes with a notable ‘first’ for the field.

Fraiser Kansteiner Oct 7, 2026 2:27pm

Wooden gavel and gold legal scale that appear to have sunlight falling on them

Halozyme wins Keytruda SC injunction in several European markets

Oct 7, 2026 11:08am

For biopharma manufacturing at speed and scale, the future is flexible

Brought to you by Resilience

How drugmakers can capitalize on the GLP-1 'consumer overlay'

Oct 7, 2026 10:00am

Clinical trials reach a new automation inflection point

Brought to you by IQVIA

Experts weigh in: If psychedelics are approved, what comes next?

Oct 7, 2026 9:00am